Correction to: Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization.

Show more authors
+ 3
R B Verheijen
E L Swart
J H Beijnen
J H M Schellens
A D R Huitema
N Steeghs

Abstract

In the original publication of the article, the second author name has been misspelled.

More about this publication

Cancer chemotherapy and pharmacology

Volume 86
Issue nr. 1
Pages 163
Publication date 01-07-2020

Full text links

Publisher website (DOI) 10.1007/s00280-020-04090-4
Europe PubMed Central 32524189
Pubmed 32524189

This site uses cookies

This website uses cookies to ensure you get the best experience on our website.